Invokana Sales Figure Witness a Dip
Invokana Sales Figure Witness a Dip
Introduction
According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.
Comments
Latest News
NC to Get $150M to Boost Opioid Treatment, Recovery
Categories: Opioids
North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid…
SRI Gets FDA OK for High-Dose Naloxone Trial
Categories: Opioids
SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.
The approval was granted under an Investigational New Drug (IND)…
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…